Overview

Study of X0002 Following Escalating Single and Multiple Doses Administered as Topical Application in Healthy Volunteers

Status:
Completed
Trial end date:
2017-03-29
Target enrollment:
Participant gender:
Summary
Primary Objectives: To evaluate the safety and tolerability of escalating single and multiple doses of X0002 administered as a topical application. Secondary Objectives: To characterize the single and and multiple pharmacokinetics of escalating doses of X0002 and its active metabolite ibuprofen as a topical application.
Phase:
Phase 1
Details
Lead Sponsor:
Tianjin XinChen-Techfields Pharma Co., LTD.